The DOI matches its Crossref record, with a small difference in title or year; 498 of the 501 references it cites were found in a registry or an index, and 1 are not checked yet; 6 of the 375 sources its claims cite were checked for support.
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Open accessVerified 2026-10-08 · 1 reference not checked yet
Overview
AI snapshot
Written from the paper’s full text.
TL;DR
This 2016 ESC/EAS guideline provides evidence-based recommendations for managing dyslipidaemias, emphasizing LDL-C as the primary treatment target with risk-stratified goals. It recommends lifestyle modification plus statins first-line, with ezetimibe, PCSK9 inhibitors, fibrates, and other agents in specific clinical settings.
Key findings
- LDL-C goals are risk-stratified: very high risk <1.8 mmol/L (70 mg/dL) and ≥50% reduction from baseline if >1.8 mmol/L; high risk <2.6 mmol/L (100 mg/dL) and ≥50% reduction if >2.6 mmol/L; moderate risk <3.0 mmol/L (115 mg/dL). Secondary targets include non-HDL-C <2.6/3.4 mmol/L and apoB <80/100 mg/dL for very high/high risk.
- In the CTT meta-analysis of >170,000 participants and 26 statin RCTs, each 1.0 mmol/L (40 mg/dL) LDL-C reduction gave a 10% proportional reduction in all-cause mortality, 20% reduction in CAD death, 23% reduction in major coronary events, and 17% reduction in stroke.
- IMPROVE-IT randomized 18,144 patients after ACS; over 7 years, 170 fewer events occurred with simvastatin plus ezetimibe vs simvastatin alone (32.7% vs 34.7%, P=0.016), with average LDL-C 1.8 vs 1.4 mmol/L and a 21% reduction in ischaemic stroke (P=0.008). PCSK9 inhibitors lower LDL-C by ~50–70%.
- Lifestyle evidence includes PREDIMED, where a Mediterranean diet supplemented with extra-virgin olive oil or nuts reduced major CV events by almost 30%; phytosterols at 2 g/day lower TC and LDL-C by 7–10%; and pharmacological n-3 fatty acids at 2–3 g/day reduce TGs up to 30%.
Methods
- This is a joint ESC/EAS Task Force guideline, not a primary study. It used a comprehensive review of published evidence, critical evaluation of diagnostic and therapeutic procedures, and graded recommendations by class and level of evidence.
- The evidence base includes RCTs, meta-analyses, observational studies, genetic data, and estimates of expected health outcomes for larger populations where data exist.
- Recommendations were developed by selected experts, reviewed by the ESC Committee for Practice Guidelines and EAS-appointed experts, and approved by the Task Force.
Limitations
- The Task Force states that RCTs have not systematically examined different LDL-C goals, so the choice of any target goal is open to debate; monitoring recommendations stem from consensus rather than evidence-based medicine.
- The paper states that evidence for lowering elevated TGs is still modest and primarily derived from subgroup or post hoc analyses, and that evidence on functional foods is incomplete, with no diet-based intervention trials of sufficient duration.
- Evident from the text: as a guideline, it synthesizes heterogeneous evidence and many recommendations rely on expert consensus and class grading rather than a single definitive trial.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
285 Not checked yet · 71 No basis given · 36 Own interpretation · 2 Supported · 2 Partly supported · 1 Mixed support · 1 Own result · accuracy not yet measured
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“Notably, ischaemic events were reduced by 21% in the SEAS trial.”
What the sources say
- Supportedcites [243] Rossebø, 2008, Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis, N Engl J Med source
The Outcome Measures section reports 148 patients with ischemic cardiovascular events in the simvastatin–ezetimibe group versus 187 in the placebo group—about 21% fewer patients. Its hazard ratio of 0.78 also shows a significant reduction, though that measure corresponds to a 22% lower hazard. (LLM, conf=0.90)
- Disputedcites [377] Cowell, 2005, A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis, N Engl J Med sourceExperimental — accuracy not yet measured
The section describing the trial’s aim identifies this study as SALTIRE, not SEAS. The secondary-end-points table reports outcomes for the SALTIRE treatment groups, not a 21% reduction in ischaemic events in SEAS. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
- Not checked yetcites [378] Chan, 2010, Effect of lipid lowering with rosuvastatin on progression of aortic stenosis: results of the aortic stenosis progression observation: measuring effects of rosuvastatin (ASTRONOMER) trial, Circulation source
plaindirectn = 1,873- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In this respect, it is relevant that a meta-analysis of the relationship between improvement of the plasma lipoprotein profile and the rate of CV events has demonstrated that non-HDL-C lowering translates into a reduction in risk independent of the mechanisms (statins, resins, diet and ileal bypass) involved.131”
What the sources say
- Partly supportedcites [131] Robinson, 2009, Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk, J Am Coll Cardiol sourceExperimental — accuracy not yet measured
The Discussion reports a similar relationship between non-HDL-C lowering and coronary heart disease risk reduction for statins and fibrates. It says only one trial each met the inclusion criteria for diet, bile acid sequestrants (resins), and surgery, so those treatments could not be evaluated in the multivariate models. Their results were broadly consistent with the relationship, but the meta-analysis did not establish that risk reduction was independent of all the listed mechanisms. (LLM, conf=0.88)
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Non-HDL-C has been shown to have a strong predictive power”
boostedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Several prospective studies have shown that apoB is equal to LDL-C and non-HDL-C in risk prediction.”
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“The causative role of HDL-C for protection against CVD has been questioned in several studies utilizing Mendelian randomization.87,89,91,92”
What the sources say
- Not checked yetcites [87] Sarwar, 2010, Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies, Lancet source
- Not checked yetcites [89] Holmes, 2015, Mendelian randomization of blood lipids for coronary heart disease, Eur Heart J source
- Not checked yetcites [91] Haase, 2010, Genetically elevated apolipoprotein A-I, high-density lipoprotein cholesterol levels, and risk of ischemic heart disease, J Clin Endocrinol Metab source
- Not checked yetcites [92] Voight, 2012, Plasma HDL cholesterol and risk of myocardial infarction: a Mendelian randomisation study, Lancet source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“In a number of meta-analyses, TGs has been shown to be an independent risk factor.96,97”
What the sources say
- Not checked yetcites [96] Sarwar, 2007, Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies, Circulation source
- Not checked yetcites [97] Hokanson, 1996, Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies, J Cardiovasc Risk source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“Several analyses have been published comparing these variables in risk algorithms, but data are inconclusive.”
What the sources say
- Not checked yetcites 83e85
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“In general, comparisons between calculated and direct LDL-C show good agreement.81”
What the sources say
- Not checked yetcites [81] Knopfholz, 2014, Validation of the Friedewald formula in patients with metabolic syndrome, Cholesterol source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“Very high levels of HDL-C have consistently not been found to be associated with atheroprotection.90”
What the sources say
- Not checked yetcites [90] Di Angelantonio, 2009, Major lipids, apolipoproteins, and risk of vascular disease, JAMA source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“However, clinical trial evidence is lacking on the effectiveness of intervening in these variables to reduce CV risk further.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- It may state two separate claims as one. 154
- Probably not a substantial claim. 44
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Oestrogen replacement therapy, despite some favourable effects on the lipid profile, has not been demonstrated to reduce CV risk and cannot be recommended for CVD prevention in women.318”
What the sources say
- Partly supportedcites [318] Manson, 2003, Estrogen plus progestin and the risk of coronary heart disease, N Engl J Med sourceExperimental — accuracy not yet measured
The subgroup analyses state that estrogen improves LDL and HDL cholesterol levels and report no demonstrated cardiac protection from the combined regimen; they also describe similar results in trials of estrogen alone. The paper’s recommendation against use for cardiovascular prevention, however, applies specifically to estrogen plus progestin. It cautions that its trial cannot distinguish estrogen’s effects from progestin’s or establish results for other formulations. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Ezetimibe further reduced LDL-C and offered additional benefit (6.4% relative risk reduction in composite clinical endpoint) in association with simvastatin in post-ACS patients. 63”
What the sources say
- Supportedcites [63] Cannon, 2015, Ezetimibe added to statin therapy after acute coronary syndromes, N Engl J Med source
The Results report lower LDL cholesterol with simvastatin–ezetimibe than with simvastatin alone. For the primary composite endpoint, the hazard ratio was 0.936, corresponding to the cited 6.4% relative reduction, in patients who had had an acute coronary syndrome. (LLM, conf=0.94)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In a post hoc analysis of the FIELD study, fenofibrate reduced CVD events by 27% in those with elevated TGs [>2.3 mmol/L (~204 mg/dL)] and reduced HDL-C (NNT ¼ 23).351”
What the sources say
- Supportedcites [351] Scott, 2009, Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study, Diabetes Care source
The Results (p. 1) define marked dyslipidemia as triglycerides ≥2.3 mmol/L plus low HDL cholesterol. The marked-dyslipidemia analysis (p. 3) reports a 27% CVD risk reduction and a number needed to treat of 23. The source uses ≥ rather than the citing sentence’s > at the threshold. (LLM, conf=0.94)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Supported
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“High TG levels are often associated with low HDL-C and high levels of small dense LDL particles.”
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The SCORE data indicate that the total CVD event risk is about three times higher than the risk of fatal CVD for men, so that a SCORE risk of 5% translates into a CVD risk of ~15% of total (fatal þ non-fatal) hard CVD endpoints; the multiplier is ~4 in women and lower in older persons.”
hedgedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“However, the direct methods have been found to be unreliable in patients with HTG and should be used with caution in these cases 72 ; also, they may underestimate very low values of LDL-C.”
What the sources say
- Not checked yetcites [72] Langlois, 2014, Clinical impact of direct HDLc and LDLc method bias in hypertriglyceridemia. A simulation study of the EAS-EFLM Collaborative Project Group, Atherosclerosis source
plainconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Low HDL-C has been shown to be a strong and independent risk factor in several studies and is included in most of the risk estimation tools available, including HeartScore.”
boostedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“A rare error occurs in patients with hyperglycerolaemia, where falsely very high values for TGs are detected.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Based on epidemiological data, levels of HDL-C associated with increased risk for men are <1.0 mmol/L (40 mg/dL) and for women are <1.2 mmol/L (48 mg/dL).”
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Some interventions resulted in significant CVD prevention, whereas others did not.”
What the sources say
- Not checked yetcites [132] Dalen, 2014, Diets to prevent coronary heart disease 1957–2013: what have we learned?, Am J Med source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Lp(a) has been found in several studies to be an additional independent risk marker; indeed, genetic data show it to be causal in the pathophysiology of atherosclerotic vascular disease and aortic stenosis.109e111”
What the sources say
- Not checked yetcites 109e111
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Furthermore, loss of function mutations are associated with low TGs as well as with reduced risk for CVD.106,107”
What the sources say
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Particular consideration was given to results from systematic reviews confirming the dose-dependent reduction in CVD with LDL-C lowering; the greater the LDL-C reduction, the greater the CV risk reduction.65,66”
What the sources say
- Not checked yetcites [65] Fulcher, 2015, Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials, Lancet source
- Not checked yetcites [66] Mihaylova, 2012, The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials, Lancet source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“although increases in HDL-C predict atherosclerosis regression”
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds.
In the paper
“PUFAs of the n-3 series have no hypocholesterolaemic effect; conversely, when they are used at high dosages (>3 g/day), the effect on LDL-C levels is either neutral or a slight increase [particularly with docosahexaenoic acid (DHA)] with a concomitant decrease of TGs.165”
What the sources say
- Not checked yetcites [165] Mensink, 2003, Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials, Am J Clin Nutr source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Stearic acid, in contrast to other SFAs (lauric, myristic and palmitic), does not increase TC levels.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Quantitatively, dietary trans fatty acids have a similar elevating effect on LDL-C to that of SFAs; however, while SFAs increase HDL-C levels, trans fats decrease them.137”
What the sources say
- Not checked yetcites [137] Estruch, 2013, Primary prevention of cardiovascular disease with a Mediterranean diet, N Engl J Med source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Moderate alcohol consumption is associated with increased HDL-C levels as compared with abstainers, with a dose-response relationship.”
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“MUFA consumption as a replacement for SFAs has almost no effect on HDL-C, while n-6 PUFAs induce a slight decrease.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“These effects are dose dependent; with a habitual fructose consumption between 15 and 20% of the total energy intake, plasma TG increases as much as 30e40%.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“both have been proven to be effective in reducing CV risk factors and, possibly, to contribute to CVD prevention.133”
What the sources say
- Not checked yetcites [133] Eckel, 2014, 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, Circulation source
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“If 1% of the dietary energy derived from SFAs is replaced by n-6 polyunsaturated fatty acids (PUFAs), LDL-C decreases by 0.051 mmol/L (2.0 mg/dL); if replaced by monounsaturated fatty acids (MUFAs), the decrease would be 0.041 mmol/L (1.6 mg/dL); and if replaced by carbohydrate, it would be 0.032 mmol/L (1.2 mg/dL).”
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Weight reduction improves insulin sensitivity and decreases TG levels.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“In this respect, both the glycaemic index and the fibre content do not seem to play a relevant role.178,179”
What the sources say
- Not checked yetcites [178] Goff, 2013, Low glycaemic index diets and blood lipids: a systematic review and meta-analysis of randomised controlled trials, Nutr Metab Cardiovasc Dis source
- Not checked yetcites [179] Bazzano, 2011, Non-soy legume consumption lowers cholesterol levels: a meta-analysis of randomized controlled trials, Nutr Metab Cardiovasc Dis source
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“In particular, the detrimental effects of a high carbohydrate diet on TGs occur mainly when refined carbohydrate-rich foods are consumed, while they are much less prominent if the diet is based largely on fibre-rich, low glycaemic index foods.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“SFAs increase HDL-C levels in parallel with LDL-C; in contrast, trans fats decrease them.137”
What the sources say
- Not checked yetcites [137] Estruch, 2013, Primary prevention of cardiovascular disease with a Mediterranean diet, N Engl J Med source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Glucose and lipid metabolism are strongly related, and any perturbation of carbohydrate metabolism induced by a high carbohydrate diet will also lead to an increase in TG concentrations.148,165”
What the sources say
- Not checked yetcites [148] Nordmann, 2006, Effects of low-carbohydrate vs low-fat diets on weight loss and cardiovascular risk factors: a meta-analysis of randomized controlled trials, Arch Intern Med source
- Not checked yetcites [165] Mensink, 2003, Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials, Am J Clin Nutr source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“While in individuals with HTG even a small amount of alcohol can induce a further elevation of TG concentrations, in the general population alcohol exerts detrimental effects on TG levels only if the intake is excessive.152,177”
What the sources say
- Not checked yetcites [152] Rimm, 1999, Moderate alcohol intake and lower risk of coronary heart disease: meta-analysis of effects on lipids and haemostatic factors, BMJ source
- Not checked yetcites [177] Brien, 2011, Effect of alcohol consumption on biological markers associated with risk of coronary heart disease: systematic review and meta-analysis of interventional studies, BMJ source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Body weight reduction also influences TC and LDL-C, but the magnitude of the effect is rather small; in grossly obese subjects, a decrease in LDL-C concentration of ~0.2 mmol/L (8 mg/dL) is observed for every 10 kg of weight loss; the reduction of LDL-C is greater if weight loss is achieved with a low fat diet.147,148”
What the sources say
- Not checked yetcites [147] Dattilo, 1992, Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis, Am J Clin Nutr source
- Not checked yetcites [148] Nordmann, 2006, Effects of low-carbohydrate vs low-fat diets on weight loss and cardiovascular risk factors: a meta-analysis of randomized controlled trials, Arch Intern Med source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“In many studies the reduction of TG levels due to weight reduction is between 20e30%; this effect is usually preserved as long as weight is not regained.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“However, fat intakes that >35% of calories are generally associated with increased intakes of both saturated fat and calories.”
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds.
In the paper
“Conversely, a low intake of fats and oils increases the risk of inadequate intakes of vitamin E and of essential fatty acids, and may contribute to unfavourable changes in HDL-C.165”
What the sources say
- Not checked yetcites [165] Mensink, 2003, Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials, Am J Clin Nutr source
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Even in the most advanced stages of the disease (critical limb ischaemia), statin therapy improved rates of 1-year mortality and major adverse CV events and increased amputation-free survival.409”
What the sources say
- Not checked yetcites [409] Westin, 2014, Association between statin medications and mortality, major adverse cardiovascular event, and amputation-free survival in patients with critical limb ischemia, J Am Coll Cardiol source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Atherosclerotic changes of retinal arteries correlate with TC, LDL-C, TG and apoB levels and also with CAD.412”
What the sources say
- Not checked yetcites [412] Tedeschi-Reiner, 2005, Relation of atherosclerotic changes in retinal arteries to the extent of coronary artery disease, Am J Cardiol source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“In patients with first-episode schizophrenia spectrum disorders, cardiometabolic risk factors were present early in the illness; this was related to the underlying disorder, unhealthy lifestyle and antipsychotic medications, which interact with each other.437”
What the sources say
- Not checked yetcites [437] Correll, 2014, Cardiometabolic risk in patients with first-episode schizophrenia spectrum disorders: baseline results from the RAISE-ETP study, JAMA Psychiatry source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“All this explains the higher prevalence of obesity, MetS, diabetes and dyslipidaemia in patients with these psychiatric diseases.438”
What the sources say
- Not checked yetcites [438] Andrade, 2013, Primary prevention of cardiovascular events in patients with major mental illness: a possible role for statins, Bipolar Disord source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“A recent meta-analysis of RCTs in subjects >65 years of age at high CV risk without established CV disease showed that statins significantly reduce the incidence of MI and stroke, but do not significantly prolong survival in the short-term.327”
What the sources say
- Not checked yetcites [327] Savarese, 2013, Benefits of statins in elderly subjects without established cardiovascular disease: a meta-analysis, J Am Coll Cardiol source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“In patients with bipolar disorder there was a reduction in life expectancy of 12e14 years.440”
What the sources say
- Not checked yetcites [440] Laursen, 2011, Life expectancy among persons with schizophrenia or bipolar affective disorder, Schizophr Res source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“In a Finnish cohort of patients with schizophrenia, life expectancy was about 2 decades less than in persons of similar age from the general population.439”
What the sources say
- Not checked yetcites [439] Tiihonen, 2009, 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study), Lancet source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“The addition of ezetimibe to simvastatin in post-ACS patients had an incremental beneficial effect for ischaemic stroke or all strokes (marginal statistical significance for the latter).63”
What the sources say
- Not checked yetcites [63] Cannon, 2015, Ezetimibe added to statin therapy after acute coronary syndromes, N Engl J Med source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Secondary prevention therapy with statins reduces the risk of recurrent stroke (by 12%), MI and vascular death.422,428”
What the sources say
- Not checked yetcites [422] Amarenco, 2009, Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention, Lancet Neurol source
- Not checked yetcites [428] Amarenco, 2006, High-dose atorvastatin after stroke or transient ischemic attack, N Engl J Med source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Among 654 patients with bipolar disorder in the Fondamental Advanced Centers of Expertise in Bipolar Disorders (FACE-BD) cohort, 18.5% met the criteria for MetS; only 11% and 28% of the patients with hypercholesterolaemia and high fasting glycaemia, respectively, were treated for these conditions.441”
What the sources say
- Not checked yetcites [441] Godin, 2014, Metabolic syndrome in a French cohort of patients with bipolar disorder: results from the FACE-BD cohort, J Clin Psychiatry source
plainn = 654- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“HIV-infected patients typically have low TC and LDL-C, as well as low HDL-C and increased TGs.430,431”
What the sources say
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“A systematic review found that the incidence of drug-induced hepatotoxicity in patients taking statins is unknown, with very few cases occurring in large-scale RCTs.212,214”
What the sources say
- Not checked yetcites [212] Law, 2006, Statin safety: a systematic review, Am J Cardiol source
- Not checked yetcites [214] Naci, 2013, Comparative tolerability and harms of individual statins: a study-level network meta-analysis of 246 955 participants from 135 randomized, controlled trials, Circ Cardiovasc Qual Outcomes source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Various empirical models of health behaviour and behaviour change theory have been shown to predict adherence, including the Theory of Planned Behaviour 466 and the Health Belief Model.467”
What the sources say
boostedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“Predictors of non-adherence with statins have been identified 450,472e474 and include their use in individuals for primary prevention as compared with their use in patients with disease or with multiple risk factors, lower income, being elderly, complex polypharmacy, cost and forgetfulness due to a lack of symptoms and psychological co-morbidities.”
What the sources say
- Not checked yetcites [450] Benner, 2002, Long-term persistence in use of statin therapy in elderly patients, JAMA source
- Not checked yetcites 472e474
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Adherence declines over the duration of treatment 450e454 ; however, this is truer in patients treated for primary compared with secondary prevention of CVD, with reported rates of up to 77% discontinuing their statins within 2 years.”
What the sources say
- Not checked yetcites 450e454
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Not surprisingly, this non-adherence has an impact on healthcare costs, morbidity, hospital readmissions and mortality.457e461”
What the sources say
- Not checked yetcites 457e461
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Despite a wealth of evidence on the efficacy and effectiveness of statins in both primary and secondary prevention, adherence remains a consistent barrier, with rates of <50% demonstrated in several studies.”
What the sources say
- Not checked yetcites 450e454
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Studies that investigated adherence to medications in long-term conditions identified factors such as high susceptibility, severity of the condition, strong intentions and high self-efficacy as being associated with good adherence, while poor lifestyle habits and low perceived behavioural control were associated with poor adherence.468,469”
What the sources say
- Not checked yetcites [468] Rich, 2015, Theory of planned behavior and adherence in chronic illness: a meta-analysis, J Behav Med source
- Not checked yetcites [469] Kamran, 2014, Determinants of patient's adherence to hypertension medications: application of health belief model among rural patients, Ann Med Health Sci Res source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“This overview also found that the use of self-management or self-monitoring programmes, as well as a regular pharmacy review of prescribed medications with a view to taking out unnecessary medications, was helpful.”
What the sources say
- Not checked yetcites [484] Ryan, 2014, Interventions to improve safe and effective medicines use by consumers: an overview of systematic reviews, Cochrane Database Syst Rev
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“At 15 months, statistically significant differences between intervention and usual care were seen in self-reported adherence and changes in systolic blood pressure and LDL-C.”
What the sources say
- Not checked yetcites [482] Thom, 2013, Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial, JAMA source
plaincorrelationaln = 2,004- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“In phase 1, factors associated with non-adherence were younger age, depression, complex regimen, poorer health insurance coverage and low social support.”
What the sources say
- Not checked yetcites [483] Castellano, 2014, A polypill strategy to improve adherence: results from the FOCUS project, J Am Coll Cardiol source
plaincorrelationaln = 2,118- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Importantly, a sizable portion of patients on hypolipidaemic or antihypertensive drug treatment fail to take their treatment adequately or to reach their therapeutic goals, 28,29 with clinical and economic consequences.30”
What the sources say
- Not checked yetcites [28] Banegas, 2011, Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study, Eur Heart J source
- Not checked yetcites [29] Kotseva, 2010, Management of cardiovascular risk factors in asymptomatic high-risk patients in general practice: cross-sectional survey in 12 European countries, Eur J Cardiovasc Prev Rehabil source
- Not checked yetcites [30] Cherry, 2009, The clinical and economic burden of nonadherence with antihypertensive and lipid-lowering therapy in hypertensive patients, Value Health source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Coronary artery disease (CAD) mortality rates could be halved by only modest risk factor reduction, 39”
What the sources say
- Not checked yetcites [39] Capewell, 2010, Cardiovascular risk factor trends and potential for reducing coronary heart disease mortality in the United States of America, Bull World Health Org source
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“Patients who have had a clinical event such as acute coronary syndrome (ACS) or a stroke are at very high risk of a further event and automatically qualify for risk factor evaluation and management (Table 6).”
What the sources say
- Not checked yetcites Table 6
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“All current guidelines on the prevention of CVD in clinical practice recommend the assessment of total CAD or CV risk, because atherosclerotic CVD is usually the product of a number of risk factors, and prevention of CVD in a given person should be adapted to his/her total CV risk: the higher the risk, the more intense the action should be.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may state two separate claims as one.
- Rests on an assumption: Atherosclerotic cardiovascular disease is usually the product of a number of risk factors.
None of the sources cited for this claim have been checked yet.
In the paper
“Targeting lower levels in the health impact pyramid will also address the socio-economic divide in CV health, which has not diminished despite major improvements in the treatment of CVD in recent decades.9,10”
What the sources say
- Not checked yetcites [9] Heidenreich, 2011, Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association, Circulation source
- Not checked yetcites [10] McConnachie, 2014, Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage study, Eur Heart J source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“the elimination of health risk behaviours would make it possible to prevent at least 80% of CVD and even 40% of cancers, thus providing added value for other chronic diseases.3,4”
What the sources say
- Not checked yetcites [3] Liu, 2012, Healthy lifestyle through young adulthood and the presence of low cardiovascular disease risk profile in middle age: the Coronary Artery Risk Development in (Young) Adults (CARDIA) study, Circulation source
- Not checked yetcites [4] Ezzati, 2004
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“A report from the National Institute for Health and Care Excellence (NICE) estimated that a UK national programme reducing population CV risk by 1% would prevent 25 000 CVD cases and generate savings of V40 million per year.38”
What the sources say
- Not checked yetcites [38] National Institute for Health and Care Excellence, 2010
hedgeddirectn = 25,000- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Most studies assessing the cost-effectiveness of prevention of CVD combine evidence from clinical research with simulation approaches, while data from randomized controlled trials (RCTs) are relatively scarce.7,10,11”
What the sources say
- Not checked yetcites [7] Mistry, 2012, Cost-effectiveness of a European preventive cardiology programme in primary care: a Markov modelling approach, BMJ Open
- Not checked yetcites [10] McConnachie, 2014, Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage study, Eur Heart J source
- Not checked yetcites [11] Ward, 2007, A systematic review and economic evaluation of statins for the prevention of coronary events, Health Technol Assess source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“The European Guidelines on CVD prevention in clinical practice (version 2012) 6 recommend use of the SCORE system because it is based on large, representative European cohort datasets.”
What the sources say
- Not checked yetcites [6] Perk, 2012, Eur Heart J source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
In the paper
“According to the WHO, policy and environmental changes could reduce CVD in all countries for <US$1 per person per year, while interventions at the individual level are considerably more expensive.37”
What the sources say
- Not checked yetcites [37] Brown, 2011, Medication adherence: WHO cares?, Mayo Clin Proc source
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Cost-effectiveness results strongly depend on parameters such as the target population's age, the overall population risk of CVD and the cost of interventions.Hence, results obtained in one country might not be valid in another.”
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Lowering blood cholesterol levels using statins 10,11,23e25 and improving blood pressure control are also cost effective.26,27”
What the sources say
- Not checked yetcites 10,11,23e25
- Not checked yetcites [26] Stevanovic, 2014, Economic evaluation of primary prevention of cardiovascular diseases in mild hypertension: a scenario analysis for the Netherlands, Clin Ther source
- Not checked yetcites [27] Wisloff, 2012, Choice of generic antihypertensive drugs for the primary prevention of cardiovascular disease—a cost-effectiveness analysis, BMC Cardiovasc Disord source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A particular problem relates to young people with high levels of risk factors; a low absolute risk may conceal a very high relative risk requiring intensive lifestyle advice.”
plainconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper may give no reason why it holds.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“The cut-off points that are used to define high risk are in part arbitrary and based on the risk levels at which benefit is evident in clinical trials.”
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Non-HDL-C is used as an estimation of the total amount of atherogenic lipoproteins in plasma (VLDL, VLDL remnants, intermediate-density lipoprotein (IDL), LDL, Lp(a)) and relates well to apoB levels.”
boostedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Social deprivation and psychosocial stress set the scene for increased risk.57”
What the sources say
- Not checked yetcites [57] Mortensen, 2015, The high-density lipoprotein-adjusted SCORE model worsens SCORE-based risk classification in a contemporary population of 30,824 Europeans: the Copenhagen General Population Study, Eur Heart J source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“For example, HDL-C modifies risk at all levels of risk as estimated from the SCORE cholesterol charts.55 Furthermore, this effect is seen in both genders and in all age groups, including older women.”
What the sources say
- Not checked yetcites [55] Cooney, 2009, HDL cholesterol protects against cardiovascular disease in both genders, at all ages and at all levels of risk, Atherosclerosis source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Most available assays are of high quality”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“ApoB is the major apolipoprotein of the atherogenic lipoprotein families (VLDL, IDL and LDL).ApoB is a good estimate of the number of these particles in plasma.”
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Non-HDL-C also includes the atherogenic TG-rich lipoproteins (VLDL, IDL and remnants)”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Of these, some are at very high risk, and the high-risk chart may underestimate risk in these countries.”
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Risk age can be used in any population regardless of baseline risk or secular changes in mortality, and therefore avoids the need for recalibration.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: unclear — It is unclear why the paper says it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Persons with documented CVD type 1 or type 2 diabetes very high levels of individual risk factors chronic kidney disease (CKD) (refer to section 9.9) are automatically at very high or high total CV risk.No risk estimation models are needed for them; they all need active management of all risk factors.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The Friedewald formula may be unreliable when blood is obtained under non-fasting conditions.”
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds.
In the paper
“Some recent guidelines recommend non-HDL-C as a better risk indicator than LDL-C.82”
What the sources say
- Not checked yetcites [82] National Institute for Health and Care Excellence, 2014
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“It should also be considered that HTG might interfere with the direct HDL-C assays.”
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“The analytical performance is good and the assays do not require fasting conditions and are not sensitive to markedly elevated TG levels.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Overall, HDL-C has a modest but useful effect in refining risk estimation, 56 but this may not be universal, as its effect may not be seen in some low-risk populations, particularly with a relatively high mean HDL-C level.57”
What the sources say
- Not checked yetcites [56] Cooney, 2009, How much does HDL cholesterol add to risk estimation? A report from the SCORE Investigators, Eur J Cardiovasc Prev Rehabil source
- Not checked yetcites [57] Mortensen, 2015, The high-density lipoprotein-adjusted SCORE model worsens SCORE-based risk classification in a contemporary population of 30,824 Europeans: the Copenhagen General Population Study, Eur Heart J source
hedgedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“These trials are consistent in showing that the higher the initial LDL-C level, the greater the absolute reduction in risk, while the relative risk reduction remains constant at any given baseline LDL-C level.”
What the sources say
- Not checked yetcites 61e71
boostedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Good immunochemical methods are available and easily run in conventional autoanalysers.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds. It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These patients are always at high risk and should receive special attention.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: unclear — It is unclear why the paper says it holds.
It may state two separate claims as one.
In the paper
“Recent work has shown that b-coefficients are not constant with ageing and that SCORE overestimates risk in older people.54”
What the sources say
- Not checked yetcites [54] Cooney, 2016, Cardiovascular risk estimation in older persons: SCORE O.P, Eur J Prev Cardiol source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Several methods for determination of Lp(a) are available, but standardization between assays is needed.112”
What the sources say
- Not checked yetcites [112] Marcovina, 2003, Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein(a) and Cardiovascular Disease: recent advances and future directions, Clin Chem source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Lp(a) has properties in common with LDL, but it contains a unique protein, apolipoprotein(a) [apo(a)], that is structurally homologous to plasminogen.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“However, each HDL particle may carry from one to five apoA1 molecules.”
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“ApoE is present in three isoforms (apoE2, apoE3 and apoE4).”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Secondary targets have also been defined by inference for non-HDL-C and for apoB; they receive a moderate grading, as they have not been extensively studied in RCTs.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Plasma apoA1 levels <120 mg/dL for men and <140 mg/dL for women correspond approximately to what is considered as low for HDL-C.”
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“ApoA1 is the major protein of HDL-C and provides a satisfactory estimate of HDL-C concentration.”
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds. It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“ApoCIII is a key regulator of TG metabolism, and high apoCIII plasma levels are associated with high plasma VLDL and plasma TGs.”
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“In FH, a genetic diagnosis is important for family screening, to establish the diagnosis in patients with borderline LDL-C and to improve patient adherence to therapy.121”
What the sources say
- Not checked yetcites [121] Nordestgaard, 2013, Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society, Eur Heart J source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may state two separate claims as one.
In the paper
“The risk is regarded as significant when Lp(a) is above the 80th percentile (50 mg/dL).109”
What the sources say
- Not checked yetcites [109] Nordestgaard, 2010, Lipoprotein(a) as a cardiovascular risk factor: current status, Eur Heart J source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“ApoE genotyping is used primarily for the diagnosis of dysbetalipoproteinaemia (apoE2 homozygosity) and is indicated in cases with severe combined hyperlipidaemia.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
In the paper
“Determination of small dense LDL may be regarded as an emerging risk factor and may be used in the future, but it is not currently recommended for risk estimation.119”
What the sources say
- Not checked yetcites [119] Mora, 2007, LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA), Atherosclerosis source
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
In the paper
“At present, the use of genotyping for risk estimation is not recommended since known risk loci account for only a small proportion of risk.120”
What the sources say
- Not checked yetcites [120] Whitfield, 2014, Genetic insights into cardiometabolic risk factors, Clin Biochem Rev
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“ApoCIII has been identified as a new potential therapeutic target that is currently being studied, but whether it has a role in clinical practice is unknown and its measurements on a routine basis are not encouraged.108”
What the sources say
- Not checked yetcites [108] Graham, 2013, Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans, Circ Res source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Several genes have been associated with CVD.”
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Ratios between atherogenic lipoproteins and HDL-C or apoA1 (TC:HDL-C, non-HDL-C:HDL-C, apoB:apoA1) are useful for risk estimation, but not for diagnosis or as treatment targets.”
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Large GWASs have been published for coronary heart disease (CHD), as well as for associated biomarkers and risk factors.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“A major disadvantage of apoB is that it is not included in algorithms for calculation of global risk, and it has not been a predefined treatment target in controlled trials.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“The measurement of Lp(a) is particularly stable over time.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“This is due not only to methodological problems, particularly inadequate sample size or the short duration of many trials included in the systematic revision, but also to the difficulty of evaluating the impact of a single dietary factor independently of any other changes in the diet.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Previous RCTs where omega-3 supplementation was beneficial were not blinded or had low use of standard CV medications (such as statins).”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Overall, the available evidence on functional foods so far identified in this field is incomplete; the major gap is the absence of diet-based intervention trials of sufficient duration to be relevant for the natural history of dyslipidaemia and CVD.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“The daily consumption of 2 g of phytosterols can effectively lower TC and LDL-C by 7e10% in humans (with a certain degree of heterogeneity among individuals), while it has little or no effect on HDL-C and TG levels. 143”
What the sources say
- Not checked yetcites [143] Musa-Veloso, 2011, A comparison of the LDL-cholesterol lowering efficacy of plant stanols and plant sterols over a continuous dose range: results of a meta-analysis of randomized, placebo-controlled trials, Prostaglandins Leukot Essent Fatty Acids source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Different commercial preparations of RYR have different concentrations of monacolins, and lower TC and LDL-C to a variable extent, 145”
What the sources say
- Not checked yetcites [145] Gordon, 2010, Marked variability of monacolin levels in commercial red yeast rice products: buyer beware, Arch Intern Med source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“The degree of LDL-C reduction is dose dependent and varies between the different statins (supplementary Figure A and supplementary Table A).191”
What the sources say
- Not checked yetcites [191] Weng, 2010, A systematic review and meta-analysis on the therapeutic equivalence of statins, J Clin Pharm Ther source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“A 10% proportional reduction in all-cause mortality and 20% proportional reduction in CAD death per 1.0 mmol/L (40 mg/dL) LDL-C reduction was reported.”
What the sources say
- Not checked yetcites [64] Baigent, 2010, Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials, Lancet source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“six trials were available for this purpose: the berberine group contained 229 patients and the control group contained 222 patients.190”
What the sources say
- Not checked yetcites [190] Lan, 2015, Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension, J Ethnopharmacol source
plainn = 229- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Poor response to statin treatment in clinical studies is to some extent caused by poor compliance, but may also be explained by a genetic background involving variations in genes of both cholesterol metabolism and of statin uptake and metabolism in the liver.192,193”
What the sources say
- Not checked yetcites [192] Chasman, 2012, Genetic determinants of statin-induced low-density lipoprotein cholesterol reduction: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial, Circ Cardiovasc Genet source
- Not checked yetcites [193] Reiner, 2014, Resistance and intolerance to statins, Nutr Metab Cardiovasc Dis source
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“The risk of major coronary events was reduced by 23% and the risk of stroke was reduced by 17% per 1 mmol/L (40 mg/dL) LDL-C reduction.”
What the sources say
- Not checked yetcites [64] Baigent, 2010, Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials, Lancet source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Foods enriched with these fibres are well tolerated, effective and recommended for LDL-C lowering at a daily dose of at least 3 g/day.186,187”
What the sources say
- Not checked yetcites [186] AbuMweis, 2010, β-glucan from barley and its lipid-lowering capacity: a meta-analysis of randomized, controlled trials, Eur J Clin Nutr source
- Not checked yetcites [187] Wolever, 2010, Physicochemical properties of oat beta-glucan influence its ability to reduce serum LDL cholesterol in humans: a randomized clinical trial, Am J Clin Nutr source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“The studies, showing a statistically significant heterogeneity, were all performed in China in people of Asian ethnicity.”
What the sources say
- Not checked yetcites [190] Lan, 2015, Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension, J Ethnopharmacol source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“This treatment seems to induce beneficial effects not only on the overall risk factor profile, but also on CV events.181”
What the sources say
- Not checked yetcites [181] Puzziferri, 2014, Long-term follow-up after bariatric surgery: a systematic review, JAMA source
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“For most individuals, a wide range of total fat intakes is acceptable and will depend upon individual preferences and characteristics.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds.
In the paper
“Smoking cessation has clear benefits on the overall CV risk, and specifically on HDL-C, but special attention should be paid in order to prevent weight gain in people who stop smoking.163”
What the sources say
- Not checked yetcites [163] Maeda, 2003, The effects of cessation from cigarette smoking on the lipid and lipoprotein profiles: a meta-analysis, Prev Med source
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Observational evidence supports the recommendation that the intake of fish (at least twice a week) and long chain n-3 fatty acids supplements at low dosage may reduce the risk of CV death and stroke in primary prevention, but have no major effects on plasma lipoprotein metabolism.183”
What the sources say
- Not checked yetcites [183] Mozaffarian, 2013, Plasma phospholipid long-chain omega-3 fatty acids and total and cause-specific mortality in older adults: a cohort study, Ann Intern Med source
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“The increased risk for myopathy with nicotinic acid has been debated, but in recent reviews no increased risk of myopathy was found with this agent.236,237”
What the sources say
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“The frequency of rhabdomyolysis has been estimated to represent 1e3 cases/100√000 patient-years.212”
What the sources say
- Not checked yetcites [212] Law, 2006, Statin safety: a systematic review, Am J Cardiol source
hedgedn = 3- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“The proteinuria induced by statins is of tubular origin and is supposed to be due to reduced tubular reabsorption and not to glomerular dysfunction.229”
What the sources say
- Not checked yetcites [229] Vidt, 2005, Statins and proteinuria, Curr Atheroscler Rep source
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Patients with mild ALT elevation due to steatosis have been studied during statin treatment and there is no indication that statins cause any worsening of liver disease.222e224”
What the sources say
- Not checked yetcites [222] Chalasani, 2004, Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity, Gastroenterology source
- Not checked yetcites [223] Vuppalanchi, 2005, Patients with elevated baseline liver enzymes do not have higher frequency of hepatotoxicity from lovastatin than those with normal baseline liver enzymes, Am J Med Sci source
- Not checked yetcites [224] Dongiovanni, 2015, Statin use and non-alcoholic steatohepatitis in at risk individuals, J Hepatol source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Current available evidence from meta-analyses suggests that the clinical benefit is largely independent of the type of statin but depends on the extent of LDL-C lowering, therefore the type of statin used should reflect the LDL-C goal in a given patient.”
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“and the risk for diabetes is higher in the elderly and in the presence of other risk factors for diabetes such as overweight or insulin resistance.227”
What the sources say
- Not checked yetcites [227] Waters, 2013, Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes, J Am Coll Cardiol source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“The benefits were significant within the first year, but were greater in subsequent years.”
What the sources say
- Not checked yetcites [64] Baigent, 2010, Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials, Lancet source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“A recent Cochrane review found that colesevelam, when added to other antidiabetic agents, showed significant effects on glycaemic control; however, more research on the impact of CV risk is required.238”
What the sources say
- Not checked yetcites [238] Ooi, 2014, Colesevelam for type 2 diabetes mellitus: an abridged Cochrane review, Diabet Med source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“In this analysis, all-cause mortality was reduced by 14%, CVD events by 27%, fatal and non-fatal coronary events by 27% and stroke by 22% per 1 mmol/L (40 mg/ dL) LDL-C reduction.”
What the sources say
- Not checked yetcites [200] Taylor, 2013, Statins for the primary prevention of cardiovascular disease, Cochrane Database Syst Rev
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“The analysis included 19 studies with different statins and with somewhat varying inclusion criteria.”
What the sources say
- Not checked yetcites [200] Taylor, 2013, Statins for the primary prevention of cardiovascular disease, Cochrane Database Syst Rev
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“A recent Cochrane analysis could not find support for beneficial effects on renal function based on studies where creatinine clearance was available, and no deleterious effects were observed.228”
What the sources say
- Not checked yetcites [228] Palmer, 2014, HMG CoA reductase inhibitors (statins) for kidney transplant recipients, Cochrane Database Syst Rev
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“In rhabdomyolysis, creatine kinase (CK) levels are elevated at least 10 times, often up to 40 times the upper limit of normal.211”
What the sources say
- Not checked yetcites [211] Stroes, 2015, Ginsberg HN;, European Atherosclerosis Society Consensus Panel. Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management, Eur Heart J source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“In clinical trials the frequency of proteinuria is in general low and in most cases is not higher than for placebo.231”
What the sources say
- Not checked yetcites [231] Davidson, 2004, Rosuvastatin safety: lessons from the FDA review and post-approval surveillance, Expert Opin Drug Saf source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“The statin-induced reduced pinocytosis is directly related to the inhibition of cholesterol synthesis.230”
What the sources say
- Not checked yetcites [230] Sidaway, 2004, Inhibitors of 3-hydroxy-3-methylglutaryl-CoA reductase reduce receptor-mediated endocytosis in opossum kidney cells, J Am Soc Nephrol source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“In the FIELD study, small but significant increases in the incidence of pancreatitis (0.8% vs. 0.5%) and pulmonary embolism (1.1% vs. 0.7%) and a nonsignificant trend toward an increase in deep vein thrombosis (1.4% vs. 1.0%) were seen in those taking fenofibrate compared with placebo; this is in line with data from other fibrate studies.261”
What the sources say
- Not checked yetcites [261] Keech, 2005, d'Emden M, Whiting M, Ehnholm C, Laakso M. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial, Lancet source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“A total of 18 144 patients were randomized and 5314 patients over 7 years experienced a CVD event; 170 fewer events (32.7 vs. 34.7%)were recorded in the group taking simvastatin plus ezetimibe (P ¼ 0.016).”
What the sources say
- Not checked yetcites [63] Cannon, 2015, Ezetimibe added to statin therapy after acute coronary syndromes, N Engl J Med source
plaindirectn = 5,314 ·- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“After two large studies with nicotinic acid, one with extended-release niacin 251 and one with niacin plus laropiprant, 252 showed no beneficial effect, but rather an increased frequency of serious adverse effects, no medication containing nicotinic acid is currently approved in Europe.”
What the sources say
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Two large randomized clinical trials [the Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides: Impact on Global Health Outcomes (AIM-HIGH) and the Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE)] using, respectively, extended release (ER) nicotinic acid vs. placebo in addition to simvastatin, and ER nicotinic acid/l”
What the sources say
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Functional foods containing phytosterols as well as plant sterolecontaining tablets additionally reduce LDL-C levels by up to 5e10% in patients taking a stable dose of a statin, and this combination is also well tolerated and safe.142,255”
What the sources say
- Not checked yetcites [142] Gylling, 2014, Plant sterols and plant stanols in the management of dyslipidaemia and prevention of cardiovascular disease, Atherosclerosis source
- Not checked yetcites [255] Abumweis, 2008, Plant sterols/stanols as cholesterol lowering agents: a meta-analysis of randomized controlled trials, Food Nutr Res
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“As compared with the overwhelming evidence for the benefits of LDL-C reduction, the evidence on the benefits of lowering elevated TG levels is still modest, and is primarily derived from subgroup or post hoc analyses.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“However, the study supports the proposition that LDL-C lowering by means other than statins is beneficial and can be performed without adverse effects.”
What the sources say
- Not checked yetcites [63] Cannon, 2015, Ezetimibe added to statin therapy after acute coronary syndromes, N Engl J Med source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Naturally occurring mutations that inactivate the protein were found to be associated with reduced plasma LDL-C and reduced risk for CAD.245”
What the sources say
- Not checked yetcites [245] Won, 2014, Inactivating mutations in NPC1L1 and protection from coronary heart disease, N Engl J Med source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Therefore this pharmacological approach is effective in the vast majority of patients, including those with heterozygous FH (HeFH) and, albeit to a lower level, those with homozygous FH (HoFH) with residual LDLR expression.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“The average LDL-C during the study was 1.8 mmol/L in the simvastatin group and 1.4 mmol/ L in patients taking ezetimibe plus simvastatin.”
What the sources say
- Not checked yetcites [63] Cannon, 2015, Ezetimibe added to statin therapy after acute coronary syndromes, N Engl J Med source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“The efficacy at reducing LDL-C is in the range of 50e70%, independent of the presence of a background therapy (statins, ezetimibe, etc.); preliminary data from phase 3 trials suggest a reduction of CV events in line with the LDL-C reduction achieved.115,116”
What the sources say
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“At a daily dose of 2 g it reduces TGs by 20e40% and LDL-C by 15e18% and increases HDL-C by 15e35%.257,277,278”
What the sources say
- Not checked yetcites [257] Canner, 1986, Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin, J Am Coll Cardiol source
- Not checked yetcites [277] Kamanna, 2008, Mechanism of action of niacin, Am J Cardiol source
- Not checked yetcites [278] Bruckert, 2010, Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis, Atherosclerosis source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Results from other meta-analyses suggest reduced major CVD events in patients with high TGs and low HDL-C in fibrate-treated patients, but no decrease in CVD or total mortality.270e272”
What the sources say
- Not checked yetcites 270e272
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“In some studies an increase of patient-reported neurocognitive effects was described.This finding requires further scrutiny.250”
What the sources say
- Not checked yetcites [250] Zhang, 2016, Comparative efficacy and safety of everolimus-eluting bioresorbable scaffold versus everolimus-eluting metallic stents: a systematic review and meta-analysis, Ann Intern Med source
hedgedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Fibrates are generally well tolerated with mild adverse effects, gastrointestinal disturbances being reported in <5% of patients and skin rashes in 2%.273”
What the sources say
- Not checked yetcites [273] Davidson, 2007, Safety considerations with fibrate therapy, Am J Cardiol source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“although a relative risk reduction is seen in the oldest subjects, the increased frequency of CAD means that the absolute number of cases associated with cholesterol is highest in this group.”
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“In the Heart Protection Study (HPS), 20 536 individuals were allocated to simvastatin or placebo.After 5 years the relative risk reduction was 18% for coronary death and 25% for coronary events.The reduction was similar in age groups <65, 65e70 and >70 years.333”
What the sources say
- Not checked yetcites [333] 2002, MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial, Lancet source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“The Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) study included patients 70e82 years of age with CVD or at high risk for CVD.330 Patients were treated with pravastatin 40 mg daily or placebo.The relative risk reduction for a combined CAD endpoint was reduced by 15%, whereas no reduction was shown for stroke.”
What the sources say
- Not checked yetcites [330] Shepherd, 2002, Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial, Lancet source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Results from a meta-analysis on blood cholesterol and vascular mortality indicates that high TC is a significant risk factor for CAD mortality at all ages, but this association is attenuated in older adults”
What the sources say
- Not checked yetcites [321] Lewington, 2007, Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths, Lancet source
- Not checked yetcites [322] Prevention of coronary heart disease in clinical practice, 1998, Recommendations of the Second Joint Task Force of European and other societies on coronary prevention, Eur Heart J source
hedgedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Diabetes itself is an independent risk factor for CVD and is associated with a higher risk of CVD, even more so in women.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Data from recent meta-analyses indicate that people with MetS have a two-fold increase in CV outcomes and a 1.5fold increase in all-cause mortality.348”
What the sources say
- Not checked yetcites [348] Mottillo, 2010, The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis, J Am Coll Cardiol source
hedgedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“In the Studies Assessing Goals in the Elderly (SAGE) trial, 893 patients 65e83 years of age with stable CAD were recruited to treatment with atorvastatin 80 mg or pravastatin 40 mg.331 The atorvastatin group had a lower all-cause mortality (HR 0.33) and a non-significant trend towards reduction in major CAD events.”
What the sources say
- Not checked yetcites [331] Deedwania, 2007, Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the Study Assessing Goals in the Elderly (SAGE), Circulation source
plaincorrelationaln = 893- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“The meta-analysis of Walsh and Pignone 314 reported a 26% reduction of CV mortality, a 29% reduction of MI and a 20% reduction of total CAD events in a cohort of 8272 females with previous CVD mainly treated with statins.”
What the sources say
- Not checked yetcites [314] Walsh, 2004, Drug treatment of hyperlipidemia in women, JAMA source
plaindirectn = 8,272- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“The rate of the composite endpoint of death from CV causes, MI or stroke was significantly lower, by 1.8 percentage points, in the combination group and the benefit of simvastatineezetimibe was consistent for women.63”
What the sources say
- Not checked yetcites [63] Cannon, 2015, Ezetimibe added to statin therapy after acute coronary syndromes, N Engl J Med source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“a metaanalysis of fibrates in the prevention of CVD in 11 590 people with T2DM showed that fibrates significantly reduced the risk of non-fatal MI by 21%, but had no effect on the risk of overall mortality or coronary mortality.353”
What the sources say
- Not checked yetcites [353] Saha, 2010, Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus—a pooled meta-analysis of randomized placebo-controlled clinical trials, Int J Cardiol source
plaindirectn = 11,590- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“The lipid profile in type 1 diabetic subjects with good glycaemic control is 'supernormal' and characterized by subnormal TGs and LDL-C, whereas HDL-C is usually within the upper normal range or slightly elevated.”
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Recent data indicate that diabetes per se increases CVD risk about two-fold on average, but the risk is subject to wide variation depending on the population.342”
What the sources say
- Not checked yetcites [342] Sattar, 2013, Revisiting the links between glycaemia, diabetes and cardiovascular disease, Diabetologia source
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Type 1 diabetes is associated with high CVD risk, in particular in patients with microalbuminuria and renal disease.355”
What the sources say
- Not checked yetcites [355] Laing, 2003, Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes, Diabetologia source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The results of these trials concordantly show that lipid-lowering therapy substantially reduces CV events in these patients, although no reduction in total mortality risk could be demonstrated.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“In a recent meta-analysis, subjects >65 years of age (n ¼ 24 674) from eight studies were included.327 Statin treatment reduced MI (RR 0.61) and stroke (RR 0.76).”
What the sources say
- Not checked yetcites [327] Savarese, 2013, Benefits of statins in elderly subjects without established cardiovascular disease: a meta-analysis, J Am Coll Cardiol source
plaindirectn = 24,674- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Supplementation with highly purified n-3 PUFAs reduced mortality in survivors of MI in one study (Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)], but failed to affect clinical outcomes in two more recent trials using modern evidence-based prevention therapies (most patients were on statins), and therefore cannot be recommended in routine practice.361”
What the sources say
- Not checked yetcites [361] Rizos, 2012, Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis, JAMA source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Results from an MI registry study in Sweden demonstrate that statin treatment is associated with lower CV mortality in very old post-MI patients without (which is important to stress) increasing the risk of cancer.337”
What the sources say
- Not checked yetcites [337] Gränsbo, 2010, Cardiovascular and cancer mortality in very elderly post-myocardial infarction patients receiving statin treatment, J Am Coll Cardiol source
boostedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Statins are effective in reducing disease activity, CV events and mortality (particularly in primary prevention) in this setting, while their discontinuation increases MI and mortality.386”
What the sources say
- Not checked yetcites [386] De Vera, 2011, Statin discontinuation and risk of acute myocardial infarction in patients with rheumatoid arthritis: a population-based cohort study, Ann Rheum Dis source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“The onset of heart failure (HF) increases the risk of mortality and morbidity three to four times compared with patients without HF.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds.
In the paper
“yet the predictive role of this biomarker (but not of carotid plaque) is somewhat compromised in light of recent data.60”
What the sources say
- Not checked yetcites [60] Vlachopoulos, 2015, Atherosclerosis source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Lipid abnormalities are common in patients who have undergone solid organ transplantation and predispose patients to the development of both atherosclerotic disease and transplant arterial vasculopathy, resulting in major vascular events.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“In patients with CKD not on dialysis, treatment with statins reduced all-cause mortality by 34%, CV mortality by 31%, CV events by 45% and stroke by 34%.”
What the sources say
- Not checked yetcites [394] Barylski, 2013, Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy–a meta-analysis of 11 randomized controlled trials involving 21,295 participants, Pharmacol Res source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Although randomized trial data have shown that statins have the potential to improve outcomes in heart transplant patients 400e402 and renal transplant patients, 403 the amounts of outcome data are not extensive.”
What the sources say
- Not checked yetcites 400e402
- Not checked yetcites [403] Navaneethan, 2009, HMG CoA reductase inhibitors (statins) for kidney transplant recipients, Cochrane Database Syst Rev
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“In patients receiving dialysis, treatment with statins had no effect on all-cause mortality and stroke, but reduced CV mortality by 21% and CV events by 19%.”
What the sources say
- Not checked yetcites [394] Barylski, 2013, Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy–a meta-analysis of 11 randomized controlled trials involving 21,295 participants, Pharmacol Res source
plaindirectn = 293- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“The results from AURORA (A study to evaluate the Use of Rosuvastatin in subjects On Regular haemodialysis: an Assessment of survival and cardiovascular events), involving 2776 patients on haemodialysis, show that rosuvastatin lowered LDL-C as expected but had no significant effect on the composite CVD endpoint.396”
What the sources say
- Not checked yetcites [396] Fellström, 2009, Rosuvastatin and cardiovascular events in patients undergoing hemodialysis, N Engl J Med source
plainn = 2,776- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“The presence of an abdominal aortic aneurysm represents a riskequivalent condition and is associated with age, male gender, personal history of atherosclerotic CVD, smoking, hypertension and dyslipidaemia, 415 while, in contrast, diabetic patients are at decreased risk.”
What the sources say
- Not checked yetcites [415] Golledge, 2006, Abdominal aortic aneurysm: pathogenesis and implications for management, Arterioscler Thromb Vasc Biol source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“PAD is a common manifestation of atherosclerosis, and such patients are at elevated risk of coronary events, with PAD representing an independent risk factor for MI and CV death.405,406”
What the sources say
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“The CV mortality in patients with stage 3 and stage 4 CKD is two-fold and three-fold higher, respectively, when compared with patients with normal renal function.391”
What the sources say
- Not checked yetcites [391] Matsushita, 2010, Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis, Lancet source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Autoimmune diseases, including rheumatoid arthritis, SLE, psoriasis and anti-phospholipid syndrome, are characterized by enhanced atherosclerosis and consequently higher CV morbidity and mortality rates compared with the general population.383e385”
What the sources say
- Not checked yetcites 383e385
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“In two large RCTs 373,374 there was no benefit on hard endpoints, such as CV mortality and non-fatal MI and stroke, in spite of a decrease in hospitalizations 373,375 and a marked reduction of LDL-C and hs-CRP in patients with mainly systolic heart failure.”
What the sources say
- Not checked yetcites [373] Kjekshus, 2007, Rosuvastatin in older patients with systolic heart failure, N Engl J Med source
- Not checked yetcites [374] GISSI-HF InvestigatorsTavazzi L, 2008, Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial, Lancet source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“However, the aetiology of stroke may influence the response to statins, and those patients with evidence of atherothrombosis underlying their cerebrovascular events appear to benefit most, while those with haemorrhagic stroke may not benefit.422”
What the sources say
- Not checked yetcites [422] Amarenco, 2009, Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention, Lancet Neurol source
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“There are no data on the effects of statins, ezetimibe or fibrates on CV events in dyslipidaemic HIV-infected patients.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper may give no reason why it holds.
- Rests on an assumption: In HIV-infected patients, lowering LDL-C with statins will reduce cardiovascular events even though outcome data for statins, ezetimibe or fibrates in this population are absent.
In the paper
“Given the benefits for adherence demonstrated with simplified dosing reported in a Cochrane overview of interventions to improve safe and effective medicines use by consumers, 484 it makes sense that a pill that contains multiple medications in one tablet will enhance adherence.”
What the sources say
- Not checked yetcites [484] Ryan, 2014, Interventions to improve safe and effective medicines use by consumers: an overview of systematic reviews, Cochrane Database Syst Rev
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
The paper relies on this without support.
Atherosclerotic cardiovascular disease is usually the product of a number of risk factors.
“because atherosclerotic CVD is usually the product of a number of risk factors”
The paper relies on this without support.
Many people have several risk factors that in combination may result in unexpectedly high total cardiovascular risk.
“since many people have several risk factors that, in combination, may result in unexpectedly high levels of total CV risk.”
The paper relies on this without support.
The strongest driver of total cardiovascular risk is age.
“The strongest driver of total CV risk is age”
The paper relies on this without support.
Women often have higher HDL-C levels.
“This is especially so in women, who often have higher HDL-C levels”
The paper relies on this without support.
Subjects with diabetes or high triglycerides often have low HDL-C levels.
“and in subjects with diabetes or with high TGs, who often have low HDL-C levels”
The paper relies on this without support.
The Friedewald formula cannot be used with high triglyceride values (>4.5 mmol/L or >400 mg/dL).
“With high TG values (>4.5 mmol/L or >400 mg/dL), the formula cannot be used.”
The paper relies on this without support.
Patients with familial hyperlipidaemia or total cholesterol above 7.5 mmol/L are always at high cardiovascular risk.
“These patients are always at high risk and should receive special attention.”
The paper relies on this without support.
Phytosterols compete with cholesterol for intestinal absorption and thereby modulate total cholesterol levels.
“Phytosterols compete with cholesterol for intestinal absorption, thereby modulating TC levels.”
The paper relies on this without support.
The hypocholesterolaemic effects of red yeast rice are related to a statin-like mechanism, inhibition of HMG-CoA reductase, by monacolins.
“Hypocholesterolaemic effects of RYR are related to a statinlike mechanism, inhibition of hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase, of monacolins, which represent the bioactive ingredient.”
The paper relies on this without support.
Statins reduce cholesterol synthesis in the liver by competitively inhibiting HMG-CoA reductase activity.
“Statins reduce the synthesis of cholesterol in the liver by competitively inhibiting HMG-CoA reductase activity.”
The paper relies on this without support.
A reduction in intracellular cholesterol concentration induces increased LDL receptor expression on hepatocytes, which increases uptake of LDL cholesterol from the blood and decreases plasma LDL cholesterol and other apoB-containing lipoproteins, including triglyceride-rich particles.
“The reduction in intracellular cholesterol concentration induces an increased expression of LDLR on the surface of the hepatocytes, which results in increased uptake of LDL-C from the blood and a decreased plasma concentration of LDL-C and other apoB-containing lipoproteins, including TG-rich particles.”
The paper relies on this without support.
Bile acids are synthesized in the liver from cholesterol and released into the intestinal lumen, but most bile acid is returned to the liver from the terminal ileum via active absorption.
“Bile acids are synthesized in the liver from cholesterol and are released into the intestinal lumen, but most of the bile acid is returned to the liver from the terminal ileum via active absorption.”
The paper relies on this without support.
Ezetimibe inhibits intestinal uptake of dietary and biliary cholesterol without affecting the absorption of fat-soluble nutrients.
“Ezetimibe is the first lipid-lowering drug that inhibits intestinal uptake of dietary and biliary cholesterol without affecting the absorption of fat-soluble nutrients.”
The paper relies on this without support.
The risk of pancreatitis is clinically significant if triglycerides exceed 10 mmol/L.
“The risk of pancreatitis is clinically significant if TGs exceed 10 mmol/L (880 mg/dL), and actions to prevent acute pancreatitis are mandatory.”
The paper relies on this without support.
Statins have significant effects on mortality as well as most cardiovascular disease outcome parameters.
“Since statins have significant effects on mortality as well as most CVD outcome parameters, these drugs are the first choice to reduce both total CVD risk and moderately elevated TG levels.”
The paper relies on this without support.
Fibrates are agonists of peroxisome proliferator-activated receptor-alpha.
“Fibrates are agonists of peroxisome proliferator-activated receptor-a (PPAR-a), acting via transcription factors regulating various steps in lipid and lipoprotein metabolism.”
The paper relies on this without support.
In HIV-infected patients, lowering LDL-C with statins will reduce cardiovascular events even though outcome data for statins, ezetimibe or fibrates in this population are absent.
“There are no data on the effects of statins, ezetimibe or fibrates on CV events in dyslipidaemic HIV-infected patients.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“For example, the current ESC/EAS lipid guidelines state that the use of purified RYR products can be considered in people with hypercholesterolemia who are not qualified for statin treatment after considering the overall CV risk(7).”
From The Role of Nutraceuticals in Statin Intolerant Patients (2018) · cites this paper as [7]
In the citing paper
“phytosterols have well-documented LDL-C lowering (Level of Recommendation: A) and the absence of adverse signals”
From The Role of Nutraceuticals in Statin Intolerant Patients (2018) · cites this paper as [7]
In the citing paper
“The current ESC/EAS lipid guidelines state that, based on the reduction of LDL-C and the absence of adverse events, the use of plant sterols/stanols can be considered: 1) in subjects with high cholesterol levels with low to intermediate CV risk who do not qualify for pharmacological treatment; 2) in combination with pharmacotherapy in high-risk or very-high-risk patients who have been statin-intol”
From The Role of Nutraceuticals in Statin Intolerant Patients (2018) · cites this paper as [7]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ 9.14. Mental disorders
“Strategies to handle CK elevations are given in Table 35 and in the supplementary material.”
§ 9.14. Mental disorders
“Table 35 Recommendations for lipid-lowering pharmacological treatment in patients with mental disorders.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ 4. Treatment targets
“For patients at a very high total CV risk, the goal is an LDL-C <1.8 mmol/L (70 mg/dL).At least a 50% reduction from baseline (if >1.8 mmol/L) should also be achieved.”
§ 9.6.1. Specific lipid management issues in acute coronary syndrome
“the dose should aim at reaching the LDL-C goal of <1.8 mmol/L (~70 mg/dL) or a 50% reduction of LDL-C as indicated in Table 11 on treatment goals.”
Citations
Cites
1 retracted
Items 401–499 of 499
Dewell, A., Hollenbeck, P. L. W., & Hollenbeck, C. B. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-2350 · Cited by 90
Merwick, Á., Albers, G. W., Arsava, E. M., Ay, H., Calvet, D., Coutts, S. B., Cucchiara, B. L., Demchuk, A. M., Giles, M. F., Mas, J.-L., et al. (2013) · Stroke · doi:10.1161/strokeaha.113.001576 · Cited by 89
Soran, H., Schofield, J. D., & Durrington, P. N. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv340 · Cited by 86
FDA drug safety communications: a narrative review and clinical considerations for older adults
Marcum, Z. A., Vande Griend, J. P., & Linnebur, S. A. (2012) · The American Journal of Geriatric Pharmacotherapy · doi:10.1016/j.amjopharm.2012.05.002 · Cited by 85
Nicotinic acid, alone and in combinations, for reduction of cardiovascular risk
Brown, B. G., & Zhao, X.-Q. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.02.039 · Cited by 84
Cherry, S. B., Benner, J. S., Hussein, M. A., Tang, S. S. K., & Nichol, M. B. (2009) · Value in Health · doi:10.1111/j.1524-4733.2008.00447.x · Cited by 83
Explaining the decline in coronary heart disease mortality in Turkey between 1995 and 2008
Unal, B., Sözmen, K., Arık, H., Gerçeklioğlu, G., Altun, D. U., Şimşek, H., Doganay, S., Demiral, Y., Aslan, Ö., Bennett, K., et al. (2013) · BMC Public Health · doi:10.1186/1471-2458-13-1135 · Cited by 82
Effect of statins on the progression of bioprosthetic aortic valve degeneration
Antonini-Canterin, F., Zuppiroli, A., Popescu, B. A., Granata, G., Cervesato, E., Piazza, R., Pavan, D., & Nicolosi, G. L. (2003) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2003.08.066 · Cited by 81
Rosuvastatin safety: lessons from the FDA review and post-approval surveillance
Davidson, M. H. (2004) · Expert Opinion on Drug Safety · doi:10.1517/14740338.3.6.547 · Cited by 80
Boyer, C., Tenenhaus‐Aziza, F., Prunet, C., Marmonier, C., Malpuech‐Brugère, C., Lamarche, B., & Chardigny, J. (2014) · British Journal Of Nutrition · doi:10.1017/s0007114514002578 · Cited by 79
Huffman, K. M., Hawk, V. H., Henes, S. T., Ocampo, C. I., Orenduff, M. C., Slentz, C. A., Johnson, J. L., Houmard, J. A., Samsa, G. P., Kraus, W. E., et al. (2012) · American Heart Journal · doi:10.1016/j.ahj.2012.04.014 · Cited by 78
Medication adherence trends with statins
Huser, M. A., Evans, T. S., & Berger, V. (2005) · Advances in Therapy · doi:10.1007/bf02849887 · Cited by 78
Risk factors for development of coronary artery disease in women with systemic lupus erythematosus
GOLDBERG, R. J., UROWITZ, M. B., IBAÑEZ, D., NIKPOUR, M., & GLADMAN, D. D. (2009) · The Journal of Rheumatology · doi:10.3899/jrheum.090011 · Cited by 78
Navarese, E. P., Kołodziejczak, M., Kereiakes, D. J., Tantry, U. S., O'Connor, C., & Gurbel, P. A. (2016) · Annals of Internal Medicine · doi:10.7326/m15-2994 · Cited by 77
Huang, Y., Li, W., Dong, L., Li, R., & Wu, Y. (2013) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.14001 · Cited by 76
Pleiotropic Effects of Statins: Evidence Against Benefits Beyond LDL-Cholesterol Lowering
Pedersen, T. R. (2010) · American Journal Cardiovascular Drugs · doi:10.2165/1158822-s0-000000000-00000 · Cited by 74
Self-citationCost-effectiveness of statins for primary cardiovascular prevention in chronic kidney disease
Erickson, K. F., Japa, S., Owens, D. K., Chertow, G. M., Garber, A. M., & Goldhaber-Fiebert, J. D. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.12.034 · Cited by 74
Intermittent nondaily dosing strategies in patients with previous statin-induced myopathy
Keating, A. J., Campbell, K. B., & Guyton, J. R. (2013) · Annals of Pharmacotherapy · doi:10.1345/aph.1r509 · Cited by 74
Genetic influences on blood lipids and cardiovascular disease risk: tools for primary prevention
Ordovas, J. M. (2009) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.2009.27113e · Cited by 74
Kelley, G. A., & Kelley, K. S. (2009) · Preventive Medicine · doi:10.1016/j.ypmed.2009.09.018 · Cited by 72
Langlois, M. R., Descamps, O. S., van der Laarse, A., Weykamp, C., Baum, H., Pulkki, K., von Eckardstein, A., De Bacquer, D., Borén, J., Wiklund, O., et al. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.12.016 · Cited by 72
Self-citationApolipoprotein C-III: Going Back to the Future for a Lipid Drug Target
Huff, M. W., & Hegele, R. A. (2013) · Circulation Research · doi:10.1161/circresaha.113.301464 · Cited by 70
National Heart, L. A. B. I. (2017) · American Academy of Pediatrics eBooks · doi:10.1542/9781610020862-part06-expert_panel · Cited by 69
Low density lipoprotein cholesterol, statins and cardiovascular events: a meta-analysis
Genser, B., & März, W. (2006) · Clinical Research in Cardiology · doi:10.1007/s00392-006-0403-x · Cited by 68
Statins for women with polycystic ovary syndrome not actively trying to conceive
Raval, A. D., Hunter, T., Stuckey, B. G. A., & Hart, R. J. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008565.pub2 · Cited by 68
United Nations' dietary policies to prevent cardiovascular disease
Mozaffarian, D., & Capewell, S. (2011) · BMJ · doi:10.1136/bmj.d5747 · Cited by 67
Mortensen, M. B., Afzal, S., Nordestgaard, B. G., & Falk, E. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv251 · Cited by 64 · cited 4×
“Overall, HDL-C has a modest but useful effect in refining risk estimation,(56) but this may not be universal, as its effect may not be seen in some low-risk populations, particularly with a relatively high mean HDL-C level.(57)”
BackgroundInfluentialDietary cholesterol and plasma lipoprotein profiles: randomized-controlled trials
Griffin, J. D., & Lichtenstein, A. H. (2013) · Current Nutrition Reports · doi:10.1007/s13668-013-0064-0 · Cited by 64
De Vera, M. A., Choi, H., Abrahamowicz, M., Kopec, J., Goycochea-Robles, M. V., & Lacaille, D. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.142455 · Cited by 64
Non-pharmacological control of plasma cholesterol levels
Poli, A., Marangoni, F., Paoletti, R., Mannarino, E., Lupattelli, G., Notarbartolo, A., Aureli, P., Bernini, F., Cicero, A., Gaddi, A., et al. (2008) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2007.10.004 · Cited by 63
Self-citationTaskinen, M.-R., Sullivan, D. R., Ehnholm, C., Whiting, M., Zannino, D., Simes, R. J., Keech, A. C., & Barter, P. J. (2009) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.108.178228 · Cited by 63
Self-citationStatins and contrast-induced acute kidney injury with coronary angiography
Gandhi, S., Mosleh, W., Abdel-Qadir, H., & Farkouh, M. E. (2014) · The American Journal of Medicine · doi:10.1016/j.amjmed.2014.05.011 · Cited by 62
Gränsbo, K., Melander, O., Wallentin, L., Lindbäck, J., Stenestrand, U., Carlsson, J., & Nilsson, J. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.01.013 · Cited by 62
Saha, S. A., & Arora, R. R. (2010) · International Journal of Cardiology · doi:10.1016/j.ijcard.2008.11.211 · Cited by 61
Droste, D. W., Iliescu, C., Vaillant, M., Gantenbein, M., Bremaeker, N. D., Lieunard, C., Velez, T., Meyer, M., Guth, T., Kuemmerle, A., et al. (2013) · Nutrition Journal · doi:10.1186/1475-2891-12-147 · Cited by 61
Godin, O., Collaborators, F. T. F. A. C. O. E. I. B. D. (.-B., Etain, B., Henry, C., Bougerol, T., Courtet, P., Mayliss, L., Passerieux, C., Azorin, J.-M., Kahn, J.-P., et al. (2014) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14m09038 · Cited by 60
Combination statin-fibrate therapy: safety aspects
Franssen, R., Vergeer, M., Stroes, E. S. G., & Kastelein, J. J. P. (2009) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00917.x · Cited by 60 · cited 1×
“The increased risk for myopathy when combining statins with other fibrates such as fenofibrate, bezafibrate or ciprofibrate seems to be small.(234,235)”
BackgroundInsights into aortic sclerosis and its relationship with coronary artery disease
Milin, A. C., Vorobiof, G., Aksoy, O., & Ardehali, R. (2014) · Journal of the American Heart Association · doi:10.1161/jaha.114.001111 · Cited by 59
Explaining the decline in coronary heart disease mortality in Portugal between 1995 and 2008
Pereira, M., Azevedo, A., Lunet, N., Carreira, H., O’Flaherty, M., Capewell, S., & Bennett, K. (2013) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.113.000264 · Cited by 59
(1992) · Archives of Internal Medicine · doi:10.1001/archinte.1992.00400190041009 · Cited by 58
(2010) · PubMed · Cited by 58
Wohl, D. A., Waters, D. D., Simpson, R. J., Richard, S., Schnell, A., Napravnik, S., Keys, J., Eron, J. J., & Hsue, P. Y. (2008) · Clinical Infectious Diseases · doi:10.1086/592116 · Cited by 57
Rivellese, A. A., Giacco, R., Annuzzi, G., De Natale, C., Patti, L., Di Marino, L., Minerva, V., Costabile, G., Santangelo, C., Masella, R., et al. (2008) · Clinical Nutrition · doi:10.1016/j.clnu.2007.07.005 · Cited by 56
Self-citationLatry, P., Molimard, M., Dedieu, B., Couffinhal, T., Bégaud, B., & Martin‐Latry, K. (2011) · BMC Cardiovascular Disorders · doi:10.1186/1471-2261-11-46 · Cited by 56
Holme, I., Cater, N. B., Færgeman, O., Kastelein, J. J. P., OLSSON, A. G., Tikkanen, M. J., Larsen, M. L., Lindahl, C., Pedersen, T. R., & Decrea, O. B. O. T. I. (2008) · Annals of Medicine · doi:10.1080/07853890801964955 · Cited by 53
Self-citationLea, L. J., & Hepburn, P. A. (2006) · Food and Chemical Toxicology · doi:10.1016/j.fct.2006.01.017 · Cited by 52
Combination therapy in dyslipidemia: Where are we now?
Catapano, A. L., Farnier, M., Foody, J. M., Toth, P. P., Tomassini, J. E., Brudi, P., & Tershakovec, A. M. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.09.026 · Cited by 52
Self-citationCholesterol and cardiovascular disease
Tyroler, H. A. (1984) · The American Journal of Cardiology · doi:10.1016/0002-9149(84)90851-8 · Cited by 52
Primary nonadherence to statin therapy: patients' perceptions.
Harrison, T. N., Derose, S. F., Cheetham, T. C., Chiu, V. Y., Vansomphone, S. S., Green, K., Tunceli, K., Scott, R. D., Marrett, E., & Reynolds, K. (2013) · PubMed · Cited by 49
Statin adherence and mortality in patients enrolled in a secondary prevention program.
McGinnis, B., Olson, K. L., Delate, T., & Stolcpart, R. S. (2009) · PubMed · Cited by 49
Statins and renovascular disease in the elderly: a population-based cohort study
Hackam, D. G., Wu, F., Li, P., Austin, P. C., Tobe, S. W., Mamdani, M. M., & Garg, A. X. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehq452 · Cited by 49
on behalf of the FIELD Study Investigators, d’Emden, M. C., Jenkins, A. J., Li, L., Zannino, D., Mann, K. P., Best, J. D., Stuckey, B. G. A., Park, K., Saltevo, J., et al. (2014) · Diabetologia · doi:10.1007/s00125-014-3344-3 · Cited by 49
Myocardial infarction and third generation oral contraceptives: aggregation of recent studies
Spitzer, W. O. (2002) · Human Reproduction · doi:10.1093/humrep/17.9.2307 · Cited by 49
Zhao, X.-Q., Krasuski, R. A., Baer, J., Whitney, E. J., Neradilek, B., Chait, A., Marcovina, S., Albers, J. J., & Brown, B. G. (2009) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.07.035 · Cited by 48
Mistry, H., Morris, S., Dyer, M., Kotseva, K., Wood, D., & Buxton, M. (2012) · BMJ Open · doi:10.1136/bmjopen-2012-001029 · Cited by 48
Self-citationReiner, ?., Tedeschi-Reiner, E., & Romi??, ?. (2005) · Clinical Drug Investigation · doi:10.2165/00044011-200525110-00003 · Cited by 47
O'Keeffe, C., Kabir, Z., O'Flaherty, M., Walton, J., Capewell, S., & Perry, I. J. (2013) · BMJ Open · doi:10.1136/bmjopen-2013-002837 · Cited by 47
Wilhelmsen, L., Svärdsudd, K., Eriksson, H., Rosengren, A., Hansson, P.-O., Welin, C., Odén, A., & Welin, L. (2011) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2010.02331.x · Cited by 47
HMG CoA reductase inhibitors (statins) for kidney transplant recipients
Navaneethan, S. D., Perkovic, V., Johnson, D. W., Nigwekar, S. U., Craig, J. C., & Strippoli, G. F. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005019.pub3 · Cited by 46
Monitoring of lipids, enzymes, and creatine kinase in patients on lipid-lowering drug therapy
Wiklund, O., Pirazzi, C., & Romeo, S. (2013) · Current Cardiology Reports · doi:10.1007/s11886-013-0397-8 · Cited by 45
Self-citationIp, C.-K., Jin, D.-M., Gao, J.-J., Meng, Z., Meng, J., Tan, Z., Wang, J.-F., & Geng, D.-F. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.04.228 · Cited by 43
Ojala, K., Repo-Tiihonen, E., Tiihonen, J., & Niskanen, L. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881107077815 · Cited by 43
Statins for primary prevention of venous thromboembolism
Li, L., Zhang, P., Tian, J. H., & Yang, K. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008203.pub3 · Cited by 42
van Gils, P. F., Over, E. A. B., Reenen, H. H. H.-V., de Wit, G. A., van den Berg, M., Schuit, A. J., & Engelfriet, P. M. (2011) · BMJ Open · doi:10.1136/bmjopen-2011-000363 · Cited by 41
Genetic insights into cardiometabolic risk factors.
Whitfield, J. B. (2014) · Europe PMC (PubMed Central) · Cited by 40
Relative safety of gemfibrozil and fenofibrate in the absence of concomitant cerivastatin use
Holoshitz, N., Alsheikh-Ali, A. A., & Karas, R. H. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.07.057 · Cited by 40
Colesevelam for type 2 diabetes mellitus: an abridged Cochrane review
Ooi, C. P., & Loke, S. C. (2014) · Diabetic Medicine · doi:10.1111/dme.12295 · Cited by 39
Plasma homocysteine and the risk of venous thromboembolism: insights from the FIELD study
Herrmann, M., Whiting, M. J., Veillard, A.-S., Ehnholm, C., SULLIVAN, D. R., KEECH, A. C., & for the FIELD study investigators (2012) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2012-0078 · Cited by 38
Primary prevention of cardiovascular disease with statins in the elderly
Reiner, Ž. (2014) · Current Atherosclerosis Reports · doi:10.1007/s11883-014-0420-6 · Cited by 38
Self-citationGuidelines for Classification of Acute Kidney Diseases and Disorders
Barry, R., & James, M. T. (2015) · The Nephron journals/Nephron journals · doi:10.1159/000441425 · Cited by 38
Arsenault, B. J., Boekholdt, S. M., Mora, S., DeMicco, D. A., Bao, W., Tardif, J.-C., Amarenco, P., Pedersen, T., Barter, P., & Waters, D. D. (2014) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2014.01.414 · Cited by 36
Self-citationCorrao, G., Scotti, L., Zambon, A., Baio, G., Nicotra, F., Conti, V., Capri, S., Tragni, E., Merlino, L., Catapano, A. L., et al. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.04.014 · Cited by 33
Self-citationAntonini-Canterin, F., Moura, L. M., Enache, R., Leiballi, E., Pavan, D., Piazza, R., Popescu, B. A., Ginghină, C., Nicolosi, G. L., & Rajamannan, N. M. (2010) · Circulation · doi:10.1161/circulationaha.109.891598 · Cited by 32
Plans-Rubió, P. (2010) · American Journal Cardiovascular Drugs · doi:10.2165/11539150-000000000-00000 · Cited by 31
The efficacy and tolerability of ezetimibe in cardiac transplant recipients taking cyclosporin
Shaw, S. M., Chaggar, P., Ritchie, J., Shah, M. K. H., Baynes, A. C., O’Neill, N., Fildes, J. E., Yonan, N., & Williams, S. G. (2009) · Transplantation · doi:10.1097/tp.0b013e318198d7d0 · Cited by 31 · cited 6×
“Some recent guidelines recommend non-HDL-C as a better risk indicator than LDL-C.”
BackgroundInfluentialZhang, X.-L., Zhu, L., Wei, Z.-H., Zhu, Q.-Q., Qiao, J.-Z., Dai, Q., Huang, W., Li, X.-H., Xie, J., Kang, L.-N., et al. (2016) · Annals of Internal Medicine · doi:10.7326/m16-0006 · Cited by 31
Peura, P., Martikainen, J., Soini, E., Hallinen, T., & Niskanen, L. (2008) · Current Medical Research and Opinion · doi:10.1185/03007990802144705 · Cited by 29
Rosengren, A. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehr364 · Cited by 29
Program, T. L. R. C. (1983) · Journal of Chronic Diseases · doi:10.1016/0021-9681(83)90138-8 · Cited by 29
Role of colesevelam in combination lipid-lowering therapy
Jones, M. R., & Nwose, O. M. (2013) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-013-0037-0 · Cited by 27
Wisløff, T., Selmer, R. M., Halvorsen, S., Fretheim, A., Norheim, O. F., & Kristiansen, I. S. (2012) · BMC Cardiovascular Disorders · doi:10.1186/1471-2261-12-26 · Cited by 26 · cited 1×
“Lowering blood cholesterol levels using statins 25 and improving blood pressure control are also cost effective.(26,27) Importantly, a sizable portion of patients on hypolipidaemic or antihypertensive drug treatment fail to take their treatment adequately or to reach their therapeutic goals,(28,29) with clinical and e…”
BackgroundReiner, Ž. (2014) · Circulation Research · doi:10.1161/circresaha.113.302952 · Cited by 26
Self-citationHe, L., Wickremasingha, P., Lee, J., Tao, B., Mendell-Harary, J., Walker, J., & Wight, D. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2013.12.033 · Cited by 25
Acute coronary syndromes in patients with chronic kidney disease
Franczyk-Skóra, B., Gluba, A., Banach, M., Rozentryt, P., Poloński, L., & Rysz, J. (2013) · Current Vascular Pharmacology · doi:10.2174/1570161111311050013 · Cited by 23
Statins and their effect on cognition: Let’s clear up the confusion
Gauthier, J. M., & Massicotte, A. (2015) · Canadian Pharmacists Journal / Revue des Pharmaciens du Canada · doi:10.1177/1715163515578692 · Cited by 23
Giang, K. W., Björck, L., Novak, M., Lappas, G., Wilhelmsen, L., Torén, K., & Rosengren, A. (2013) · European Heart Journal · doi:10.1093/eurheartj/ehs458 · Cited by 22
Open letter raises concerns about NICE guidance on statins
Wise, J. (2014) · BMJ · doi:10.1136/bmj.g3937 · Cited by 21
Andrade, C. (2013) · Bipolar Disorders · doi:10.1111/bdi.12130 · Cited by 18
Vidt, D. G. (2005) · Current Atherosclerosis Reports · doi:10.1007/s11883-005-0046-9 · Cited by 18
Loncar, G., Barthelemy, O., Berman, E., Kerneis, M., Petroni, T., Payot, L., Choussat, R., Silvain, J., Collet, J.-P., Helft, G., et al. (2015) · Archives of Cardiovascular Diseases · doi:10.1016/j.acvd.2015.06.001 · Cited by 17
Killoran, A., & White, P. (2010) · Journal of Public Health · doi:10.1093/pubmed/fdp128 · Cited by 16
Neyt, M., Laet, C. D., Brabandt, H. V., Franco, O., & Ramaekers, D. (2009) · Acta Cardiologica · doi:10.2143/ac.64.1.2034354 · Cited by 15
Stevanović, J., O’Prinsen, A. C., Verheggen, B. G., Schuiling-Veninga, N., Postma, M. J., & Pechlivanoglou, P. (2014) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.01.008 · Cited by 12
Statins for primary prevention of venous thromboembolism
Li, L., Sun, T., Zhang, P., Tian, J., & Yang, K. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008203.pub2 · Cited by 12
Statins for Cardiovascular Prevention According to Different Strategies: A Cost Analysis
Ito, M. K., Nanchen, D., Rodondi, N., Paccaud, F., Waeber, G., Vollenweider, P., & Marques-Vidal, P. (2011) · American Journal Cardiovascular Drugs · doi:10.2165/11586760-000000000-00000 · Cited by 11
HMG CoA reductase inhibitors (statins) for kidney transplant recipients
Navaneethan, S. D., Perkovic, V., Nigwekar, S. U., Johnson, D. W., Craig, J. C., & Strippoli, G. F. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005019.pub2 · Cited by 11
Finegold, J. A., & Francis, D. P. (2015) · European Journal of Preventive Cardiology · doi:10.1177/2047487314550805 · Cited by 9
Huffman and colleagues' response to Abramson and colleagues' article on statins in low risk people
Huffman, M. D., Taylor, F. C., & Ebrahim, S. B. J. (2014) · BMJ · doi:10.1136/bmj.g1520 · Cited by 5
Research works printed but not linked: 2
- Hinchcliffe, 2011, Patient Adherence to Treatment with Statins for the Prevention of Cardiovascular Disease, Cardiff: Public Health Wales NHS Trust
- Jackson, 2014, Applying COM-B to medication adherence, Eur Health Psychol, 16, 7
Cited by
Sorted by citations
Ibanez, B., James, S., Agewall, S., Antunes, M. J., Bucciarelli-Ducci, C., Bueno, H., Caforio, A. L. P., Crea, F., Goudevenos, J. A., Halvorsen, S., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx393 · Cited by 9,728
Self-citationArnett, D. K., Blumenthal, R. S., Albert, M. A., Buroker, A. B., Goldberger, Z. D., Hahn, E. J., Himmelfarb, C. D., Khera, A., Lloyd-Jones, D., McEvoy, J. W., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000678 · Cited by 4,536
Ference, B. A., Ginsberg, H. N., Graham, I., Ray, K. K., Packard, C. J., Bruckert, E., Hegele, R. A., Krauss, R. M., Raal, F. J., Schunkert, H., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx144 · Cited by 3,962
Self-citation2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease
Arnett, D. K., Blumenthal, R. S., Albert, M. A., Buroker, A. B., Goldberger, Z. D., Hahn, E. J., Himmelfarb, C. D., Khera, A., Lloyd-Jones, D., McEvoy, J. W., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.03.010 · Cited by 1,896
Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol
Ray, K. K., Wright, R. S., Kallend, D., Koenig, W., Leiter, L. A., Raal, F. J., Bisch, J. A., Richardson, T., Jaros, M., Wijngaard, P. L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1912387 · Cited by 1,665
Metadata
- Authors
- Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., Reiner, Ž., Riccardi, G., Taskinen, M.-R., Tokgozoglu, L., Verschuren, W. M. M., Vlachopoulos, C., Wood, D. A., & Zamorano, J. L.
- ORCID
- Venue
- Atherosclerosis
- Publisher
- Elsevier BV
- Published
- 2016-10
- Volume
- 253
- Pages
- 281-344
- ISSN
- 0021-9150 (ISSN-L)
- OpenAlex
- W2509676484
- Semantic Scholar
- b1dcd574e6b384735f3de7ecc8fb2020e40c3483
- Cited by
- 1,582
- References
- 501
- Citations by year
- 2026: 6 · 2025: 45 · 2024: 104 · 2023: 116 · 2022: 155 · 2021: 124 · 2020: 182 · 2019: 298 · 2018: 280 · 2017: 234 · 2016: 33
- FWCI
- 312.02
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Atherosclerosis (publishedVersion)
- PubMed (publishedVersion)
- Työväentutkimus Vuosikirja (submittedVersion, other-oa)
- Utrecht University Repository (Utrecht University) (submittedVersion)
- Funders
- National Institute for Health and Care Research (NF-SI-0508-10312)
- European Society of Cardiology
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Keywords
- dyslipidemia, dyslipidemia management, cardiovascular risk, lipid-lowering therapy, cardiovascular disease prevention, ESC/EAS guidelines
- MeSH terms
- Cardiology, Humans, Dyslipidemias, Atherosclerosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-08, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-08 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
